NAV

Lafutidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lafutidine
DrugBank Accession Number
DB12770
Background

Lafutidine has been investigated in Peptic Ulcer, Community-acquired Pneumonia, and Gastroesophageal Reflux Disease (GERD).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 431.55
Monoisotopic: 431.1878776
Chemical Formula
C22H29N3O4S
Synonyms
  • Lafutidine
External IDs
  • FRG 8813
  • FRG-8813
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Lafutidine H2-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmphetamineAmphetamine may decrease the sedative activities of Lafutidine.
AmprenavirLafutidine can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsunaprevirLafutidine can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtazanavirLafutidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
BenzphetamineBenzphetamine may decrease the sedative activities of Lafutidine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Protecadin

Categories

ATC Codes
A02BA08 — Lafutidine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alkyl aryl ethers. These are organic compounds containing the alkyl aryl ether functional group with the generic formula R-O-R' , where R is an alkyl group and R' is an aryl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Alkyl aryl ethers
Alternative Parents
Aralkylamines / Piperidines / Pyridines and derivatives / Furans / Heteroaromatic compounds / Amino acids and derivatives / Trialkylamines / Sulfoxides / Secondary carboxylic acid amides / Sulfinyl compounds
show 6 more
Substituents
Alkyl aryl ether / Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Furan
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
49S4O7ADLC
CAS number
118288-08-7
InChI Key
KMZQAVXSMUKBPD-DJWKRKHSSA-N
InChI
InChI=1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2-
IUPAC Name
2-[(furan-2-yl)methanesulfinyl]-N-[(2Z)-4-({4-[(piperidin-1-yl)methyl]pyridin-2-yl}oxy)but-2-en-1-yl]acetamide
SMILES
O=C(CS(=O)CC1=CC=CO1)NC\C=C/COC1=NC=CC(CN2CCCCC2)=C1

References

General References
Not Available
Human Metabolome Database
HMDB0240216
KEGG Drug
D01131
PubChem Compound
5282136
PubChem Substance
347828955
ChemSpider
4445337
ChEBI
31759
ChEMBL
CHEMBL1742461
PharmGKB
PA166110255
Wikipedia
Lafutidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionAspiration of Gastric Contents1
3CompletedTreatmentErosive Esophagitis1
3CompletedTreatmentGastroesophageal Reflux1
1CompletedBasic ScienceGastritis Chronic1
1CompletedOtherPeptic Ulcer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.243 mg/mLALOGPS
logP2.59ALOGPS
logP0.86Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)8.87Chemaxon
pKa (Strongest Basic)7.94Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area84.67 Å2Chemaxon
Rotatable Bond Count11Chemaxon
Refractivity120.24 m3·mol-1Chemaxon
Polarizability46.25 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-00di-0319500000-21e5d3163103c305767b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0uec-0629700000-2cad78fc15f4386b3645
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0319500000-21e5d3163103c305767b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-6207900000-6f18ee8be96400a8cd73
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0fam-2925200000-403085c6afb3f1b915b6
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01sj-5982700000-735f91aa88d1fa5be1e6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-03fr-9821100000-15eebc3bd387725b5289
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01qc-5922100000-96cb12a7b64c75a06d29
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03ec-6920200000-999aa58d566cd66637d3
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-208.1096231
predicted
DarkChem Lite v0.1.0
[M-H]-207.2989
predicted
DeepCCS 1.0 (2019)
[M+H]+207.1843231
predicted
DarkChem Lite v0.1.0
[M+H]+209.6747
predicted
DeepCCS 1.0 (2019)
[M+Na]+207.0933231
predicted
DarkChem Lite v0.1.0
[M+Na]+216.83588
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2016 00:08 / Updated at February 21, 2021 18:53